Status:
COMPLETED
N-3 Fatty Acids as the First-line Antidepressant Therapy: From Biomarkers to Clinical Subtypes
Lead Sponsor:
National Science and Technology Council, Taiwan
Conditions:
Major Depressive Disorder
Eligibility:
All Genders
18-65 years
Phase:
NA
Brief Summary
Investigate the clinical subtypes and the biological markers to personalize the use n-3 PUFAs (EPA, DHA, and EPA/DHA) in MDD.
Detailed Description
In this proposal, the investigators aim to explore the clinical subtypes and biological markers to personalize the use n-3 PUFAs (EPA, DHA, and EPA/DHA) in MDD. By stratifying the subjects with (versu...
Eligibility Criteria
Inclusion
- the diagnostic criteria of DSM-IV for MDD
- 18 to 65 years old
- pre-study ratings of 18 or greater on the 21-item Hamilton Rating Scale for Depression (HAMD)
- physically healthy under comprehensive evaluations in medical history, physical examination, and laboratory parameters tests
- have not received any psychiatric treatment in 2 weeks
- competent to receive a full explanation of this study and give written informed consent.
Exclusion
- a recent or past history of other DSM-IV AxisI diagnoses besides unipolar major depression, including psychotic disorders, organic mental disorders, impulse control disorders, substance use disorder or substance abuse (last 6 months prior to the study), and bipolar disorders
- AxisII diagnoses, including borderline and antisocial personality disorder
- a notable medical comorbidity
- acutely suicidal ideation and attempt were noted that close monitoring such as hospitalization is necessary
- regular consumption of omega-3 PUFAs supplements or a habit of eating fish equal or more than 4 times per week
Key Trial Info
Start Date :
July 1 2015
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2018
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT03871088
Start Date
July 1 2015
End Date
December 1 2018
Last Update
March 12 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
China Medical University Hospital
Taichung, Taiwan, 404